1776112-90-3

Basic information

• Product Name: N-((3R,4R)-4-fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidin-3-yl)acrylamide
• Synonyms: N-((3R,4R)-4-fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidin-3-yl)acrylamide;PF-06747775;CPI-637;N-[(3R,4R)-4-fluoro-1-[6-[(3-methoxy-1-methylpyrazol-4-yl)amino]-9-methylpurin-2-yl]pyrrolidin-3-yl]prop-2-enamide
• CAS NO: 1776112-90-3
• Molecular Formula: C18H22FN9O2
• Molecular Weight: 415.4247832
• Mol File: 1776112-90-3.mol

Chemical Properties

• Appearance: /
• Storage Temp.: room temp
• CAS DataBase Reference: N-((3R,4R)-4-fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidin-3-yl)acrylamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-((3R,4R)-4-fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidin-3-yl)acrylamide(1776112-90-3)
• EPA Substance Registry System: N-((3R,4R)-4-fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidin-3-yl)acrylamide(1776112-90-3)

Safety Data

• Hazardous Substances Data: 1776112-90-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-((3R,4R)-4-fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidin-3-yl)acrylamide is used as an antineoplastic agent for targeting the epidermal growth factor receptor (EGFR) mutant form T790M. Its application is based on its ability to inhibit the growth and proliferation of cancer cells that express this specific EGFR mutation, which is often associated with resistance to standard EGFR inhibitors.
The compound's antineoplastic activity is attributed to its interaction with the EGFR T790M mutation, which is a common resistance mechanism in non-small cell lung cancer (NSCLC) patients treated with first-generation EGFR inhibitors. By targeting this mutation, N-((3R,4R)-4-fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidin-3-yl)acrylamide may help overcome resistance and improve treatment outcomes for patients with EGFR T790M-positive tumors.
Furthermore, the compound's oral bioavailability suggests that it can be administered conveniently, potentially improving patient compliance and quality of life. Its development and optimization in the pharmaceutical industry may lead to new treatment options for patients with EGFR T790M-mutated cancers, offering a promising avenue for cancer research and therapeutic intervention.

Upstream product

• 1651-29-2 6-chloro-2-fluoropurine 

Relevant articles and documents

Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants

Mutant epidermal growth factor receptor (EGFR) is a major driver of non-small-cell lung cancer (NSCLC). Marketed first generation inhibitors, such as erlotinib, effect a transient beneficial response in EGFR mutant NSCLC patients before resistance mechani

PURINE DERIVATIVES

The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, G, ring A, ring B, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, and m are defined herein. The novel purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.